Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.oculusis.com.
Aug 30, 2016
Oculus Innovative Sciences Launches Lasercyn™ into U.S. Dermatology Market for Use Following Laser Procedures, Microdermabrasions and Chemical Peels
Aug 24, 2016
Oculus Innovative Sciences Receives U.S. FDA Approval for New Post-Dermal-Procedures Product for Removal of Foreign Material Including Microorganisms
Aug 11, 2016
Oculus Innovative Sciences Receives Australian Approvals to Market Sterile Microcyn®-Based Antimicrobial Solutions and Hydrogel Dressings
This website contains forward-looking statements based on certain assumptions and expectations. For this purpose, any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to our product development, success of clinical trials, obtaining the requisite regulatory approvals, market acceptance of our product, our ability to protect our intellectual property and future financial results. For a discussion of other factors that may cause Oculus’ actual results to differ from those projected, expressed or implied by the forward looking statements, please refer to the Company's Registration Statement on Form S-1 as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.